Mabwell(02493.HK): Injection 9MW5211 Approved by NMPA for Clinical Trials in Multiple Sclerosis
NewTimeSpace News: On June 24, 2026,Mabwell(02493.HK) released a voluntary announcement stating that the company has received the Approval Notice for Drug Clinical Trials issued and verified by the National Medical Products Administration, which approves Injection 9MW5211 to carry out clinical trials targeting the indication of multiple sclerosis.
According to the announcement, 9MW5211 is a highly specific depleting innovative antibody independently developed by 3SBio Genmab. It selectively recognizes and eliminates pathogenic immune cells, blocks immune cascade reactions, and alleviates disease progression.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Mabwell(02493.HK) Elects Dr. Gui Xun as Employee Representative Director
- Mabwell (02493.HK) Sets Offer Price at HK$27.64, Expected to List on April 28
- Mabwell (02493.HK) Commences Hong Kong IPO, Secures US$53 Million from 6 Cornerstone Investors
- Mabwell-B (02493.HK)： 6MW5311 Clinical Trial Application Approved by NMPA
- Mabwell-B (02493.HK): 6MW5311 Injection Receives FDA Clinical Trial Approval as World’s First LILRB4/CD3-Targeted TCE Innovative Drug
